Some of these biomarkers predicted the response to fibroblast growth factor receptor (FGFR) inhibitors, which target FGFR2-fusions in ICCA (Table 1, Figure 1). The gene discussed is FGFR2; the disease is infantile convulsions and choreoathetosis.